Metrics to compare | PHR | Sector Sector - Average of metrics from a broad group of related Consumer Non-Cyclicals sector companies | Relationship RelationshipPHRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −12.7x | 2.1x | 11.5x | |
PEG Ratio | 0.32 | 0.03 | 0.03 | |
Price/Book | 3.8x | 1.9x | 1.5x | |
Price / LTM Sales | 21.8x | 1.1x | 0.9x | |
Upside (Analyst Target) | - | 12.4% | 27.8% | |
Fair Value Upside | Unlock | 18.7% | 14.3% | Unlock |
Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. It also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, the company is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug; and research and development at pulmonary fibrosis, respiratory tract infections, including viral infections, COVID-19, inflammatory diseases, metabolic diseases and other therapeutic applications. Pharmena S.A. was founded in 2002 and is based in Lódz, Poland. Pharmena S.A. operates as a subsidiary of Pelion S.A.